Event

14

November 2018

The State of Diabetes in Canada: The Human & Economic Costs of an Epidemic

11:30am-1:30pm | King Edward Hotel - 37 King Street East, Toronto

Right now, five million Canadians are living with diabetes and six million more are at risk of developing it soon. Since 2000, the number of Canadians with diabetes has doubled, such that now one Canadian is diagnosed with this progressive, chronic disease every three minutes.

By any definition, a disease affecting this proportion of our population is an epidemic.

Beyond the immeasurable human toll, treating diabetes costs our health-care system — and therefore every tax paying Canadian — $28 billion per year. Within a decade it will soar to $40 billion per year. Canada can no longer afford to ignore the impact of diabetes on individuals, families, our healthcare system and the economy.

With moderation by André Picard, join the EC for a discussion between Dr. Jan Hux, President & CEO of Diabetes Canada and Brian Hilberdink, President of Novo Nordisk Canada Inc. as they uncover the human and economic costs of this silent epidemic in Canada.

- Lunch will be served -

Member price:
Individual seat: $89 +HST
Table (seats 10): $800 +HST

Regular price:
Individual seat: $110 +HST
Table (seats 10): $990 +HST

Important:
- For information about accessibility, please email peters@economicclub.ca
- Dietary restriction notes and meal requests must be submitted to peters@economicclub.ca by Wednesday, November 7, 2018

*The views expressed on the Economic Club platform are not that of the Economic Club or its affiliates but of the speakers alone and the organizations they represent*

Thank you to our Title Sponsors:

The State of Diabetes in Canada: The Human & Economic Costs of an Epidemic

André Picard

Health Columnist
The Globe and Mail

André Picard

André Picard is the health columnist at The Globe and Mail, where he has been a staff writer since 1987.

He is also the author of five books. His current bestseller is a collection of columns entitled “Matters of Life and Death: Public Health Issues in Canada.”

André is a graduate of the University of Ottawa and Carleton University and has received honorary doctorates from six universities, most recently the U of T.

Brian Hilberdink

President
Novo Nordisk Canada Inc.

Brian Hilberdink

Brian Hilberdink is the President of Novo Nordisk Canada. His 22-year career includes several years at the company’s headquarters in Denmark in the Global Marketing organisation, in addition to a variety of roles with Novo Nordisk in the U.S. Brian is an active contributor on the Board of Innovative Medicines Canada and BIOTECanada, and is also a founding member of the Diabetes Canada Impact Council.

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given it experience and capabilities that also enable it to help people defeat obesity, hemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries, and markets its products in more than 170 countries.

Jan Hux

President & CEO
Diabetes Canada

Jan Hux

Jan Hux is the President and CEO of Diabetes Canada. Her background is as a clinician-scientist, trained as a general internist and health services researcher. For 20 years she held a variety of research and executive roles at the Institute for Clinical Evaluative Sciences (ICES) in Ontario, where she was responsible for developing and leading the diabetes health services research portfolio. She has over 100 peer-reviewed publications.

Jan joined Diabetes Canada in 2012, and in her roles as Chief Science Officer and, more recently President, she has been a vocal advocate for the diabetes cause. She sees the need to create population impact through healthy public policy, evidence-informed healthcare and innovative research.

Our Sponsors